Comparison of Quality of Life and Changes Experienced by Patients After Epilepsy Surgery
- Disease/Condition
- Epilepsy
- Drug/Device/Intervention
- Epilepsy Surgery Satisfaction Questionnaire (ESSQ-19)
- Study type
- Observational
- Intervention type
- other
- Primary sponsor
- University Hospital, Toulouse
- Location
- Toulouse, France
- Phase
- N/A
- Start date
- Dec 01, 2023
- End date
- Dec 01, 2024
- Enrollment
- 160 participants
Evaluation of the changes felt by patients
Epilepsy is one of the most common chronic neurological diseases. According to data from the
 World Health Organization (WHO), it affects 0.5 to 1% of the population, or around 70 million
 people world-wide and around 600,000 in France. There are several more or less severe forms
 of epilepsy depending on the type of epileptic seizures and the frequency of these seizures.
 About 30% of epileptic patients respond poorly to well-conducted medical treatment, which
 makes the number of so-called drug-resistant patients estimated at between 100,000 and
 150,000 patients.
 
 Epilepsy surgery is possible in some cases of drug-resistant epilepsy and can lead to
 complete seizure control. Beyond the impact on the control of seizures, surgery can have an
 impact on the lives of patients at the psychological, emotional and cognitive level, with
 consequences on their socio-professional but also personal life. Thus the impact on the daily
 life of patients after epilepsy surgery can vary greatly from one patient to another and the
 personal feelings of operated patients do not always seem to correspond to the objective
 elements collected by doctors. 2.3 The investigators want to retrospectively assess the
 satisfaction and quality of life of patients operated on for more than 2 years based on their
 epileptological results (frequency of seizures).
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06035965
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06035965 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Toulouse and is currently Not yet recruiting. The study focuses on Epilepsy. Target enrollment is 160 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.